
Invivyd Inc (IVVD) Stock Forecast & Price Target
Invivyd Inc (IVVD) Analyst Ratings
Bulls say
Invivyd Inc is well-positioned within the lucrative COVID-19 vaccine market, which generated approximately $56 billion in revenue in 2022, with its antibody candidates promising enhanced protection against viral diseases. The company has secured FDA approval for its Phase 3 REVOLUTION program, which, if successful, could significantly expand the market opportunity for its monoclonal antibody candidate VYD2311, potentially establishing its superiority over existing mRNA vaccines. Additionally, VYD2311's incorporation of half-life extension technology suggests a best-in-class potential that could contribute to a projected market growth to $3-4 billion globally by 2030, highlighting a favorable outlook for Invivyd's financial future.
Bears say
Invivyd Inc faces a negative outlook primarily due to the disappointing results from the STAMP trial, which revealed a 200-fold decrease in activity of its antibody candidates against the omicron variant, undermining earlier optimistic projections. Additionally, the company's potential market has been further constricted as vaccination rates for COVID-19 and influenza continue to decline, particularly among vulnerable populations such as the elderly and immunocompromised, who would require robust protection. These factors contribute to an overall diminished commercial opportunity, significantly impacting the company's financial prospects and viability in the competitive landscape of infectious disease therapeutics.
This aggregate rating is based on analysts' research of Invivyd Inc and is not a guaranteed prediction by Public.com or investment advice.
Invivyd Inc (IVVD) Analyst Forecast & Price Prediction
Start investing in Invivyd Inc (IVVD)
Order type
Buy in
Order amount
Est. shares
0 shares